Boise Cascade (BCC)

Investors need to pay close attention to BCC stock based on the movements in the options market lately.

Medicus Pharma (NASDAQ:MDCX) announced that its SKNJCT-004 Phase 2 clinical study, a non-invasive treatment for Basal Cell Carcinoma (BCC) of the skin, has begun patient recruitment in Cleveland clini...

US Food and Drug Administration (FDA) has accepted the company's Type C meeting request and SKNJCT-003 Phase 2 study has randomized more than 75% of patients Philadelphia, Pennsylvania--(Newsfile Corp...

Boise Cascade's integration of AI and robotics could drive significant efficiency and EBITDA margin improvements, setting it apart from smaller competitors. The company's integrated production and dis...

Boise Cascade Company (NYSE:BCC ) Q2 2025 Earnings Conference Call August 5, 2025 11:00 AM ET Company Participants Chris Forrey - Vice President of Finance & Investor Relations Joanna Barney - Executi...

Boise Cascade (BCC) Q2 EPS Drops 42%

Boise Cascade (BCC) came out with quarterly earnings of $1.64 per share, missing the Zacks Consensus Estimate of $1.69 per share. This compares to earnings of $2.84 per share a year ago.

BOISE, Idaho--(BUSINESS WIRE)--Boise Cascade Company ("Boise Cascade," the "Company," "we," or "our") (NYSE: BCC) today reported net income of $62.0 million, or $1.64 per share, on sales of $1.7 billi...

BOISE, Idaho--(BUSINESS WIRE)--Boise Cascade Company's (Boise Cascade or the Company) (NYSE: BCC) Board of Directors declared a quarterly dividend of $0.22 per share, an increase of $0.01 per share or...

Boise Cascade (BCC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.